Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$333.85
▼ $2.82 (-0.8%)
Market data updated: 09/21 08:49 PM
Fundamentals updated: 09/21/2026
News analyzed: 09/21/2026
Market Cap
$9.88B
Day Range
$332.46 - $340.88
52-Week Range
$158.08 - $382.54
Beta
—
Next Earnings
02.11.2026
Support
$297.02
Resistance
$373.31
KRYS is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+104.1% (1Y)
Strengths: 11/27 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 33.9%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $160.94 vs. price $333.85 (-51.8%)
Fair Value
Signal tension
Growth scores strong (82/100), but fair-value analysis scores this stock as relatively expensive (33/100) — the growth story and the current price aren't fully aligned.
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
as of 09/10/202656
This Week
67
7D Ago
↓ -11
Weakening
Technical
23
7D Ago: 68
↓ -45
Fundamental
71
7D Ago: 71
→ 0
Growth
82
7D Ago: 82
→ 0
Valuation
33
7D Ago: 33
→ 0
News
100
7D Ago: 100
→ 0
Quality
58
7D Ago: 58
→ 0
Risk
56
7D Ago: 56
→ 0
Biggest Declines
📊 Score History
56
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
17d ago · $371.47
Evidence: Euphoria score crossed 55 (now 55)
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
56 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
70
$356.19
Now
56
$333.85
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
82
Quality
58
Value
33
Momentum
23
Risk
56
Sentiment
100
Fundamental
71
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Krystal Biotech, Inc. (KRYS) highlights its strong stock performance, with a 13.4% gain in a month driven by positive momentum around its Vyjuvek product and an expanding genetic medicine pipeline. The company is positioning itself for multi-product growth, reinforcing investor confidence. Additionally, Krystal will participate in the 2026 Cantor Global Healthcare Conference, with management scheduled for a fireside chat and investor meetings. Insider sales worth nearly $9 million were also reported.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Krystal Biotech, Inc.. News trend score: 100. Reason: 10 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
37
🎯 Conviction (vs. Emotion)
42
Psychology
45
Fundamentals
71
Technical
23
Valuation
33
The price rise has far outpaced the actual improvement in fundamental data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price (3M)
-2%
Market Narrative
65
Fundamental Reality
42
Narrative Gap
+23
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests traders are prioritizing short-term momentum and valuation extremes, with overconfidence and euphoria dominating. The narrative-reality gap (40) implies optimism may outpace fundamentals, while anchoring near resistance could limit upside. Herding signals peer comparisons are influencing decisions, but FOMO’s momentum-driven volume suggests traders are less concerned with downside risk. The key question: will momentum sustain despite valuation disconnects, or will anchoring near resistance trigger profit-taking?
Updated: 09/09/2026, 12:47 AM
What could change this?
👥 What the crowd believes
"KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence"
"Krystal Biotech will participate in the 2026 Cantor Global Healthcare Conference"
"Krystal Biotech (KRYS) reported earnings 30 days ago... Up 12% since last earnings report"
"Krystal Biotech Insider Sold Shares Worth $8,983,084"
📈 8D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Benjamin Graham — 18/100
🗣️ Why do they disagree?
Based on Walter Bagehot's documented liquidity principles, the model estimates a perfect 100 score, indicating strong ability to survive a credit squeeze. Peter Lynch and Philip Fisher, focusing on growth and company quality, also assign very high scores (96 and 95), reflecting that the price appears disconnected from growth and that the firm meets Fisher's quality criteria. Value‑oriented frameworks such as Benjamin Graham's defensive and enterprising criteria give low scores (18 and 31), and the efficient‑market view (Malkiel & Bogle) rates it only 37, showing doubts about cheapness and index‑beating potential. Mid‑range assessments from Howard Marks, Gerald Loeb, Morgan Housel, and others sit in the 30‑56 range, highlighting concerns about cycle timing, risk, and moderate attractiveness.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟢 96
Growth candidate — the price hasn't caught up to the growth
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 95
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 91
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 68
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 59
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 58
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 53
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 40
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 40
Somewhere in the middle of the cycle
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 37
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 36
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 31
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 31
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 18
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Based on the last 281 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (1 bullish · 9 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
A pattern consistent with an early/mid distribution phase — a trading range after an advance with declining volume.
Medium confidence
$297.02
Range Bottom
$373.31
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
41.5%
Net Margin
52.6%
EBITDA Margin
41.5%
ROE
16.8%
ROA
15.4%
ROIC
—
EPS
$7.08
Cash
$496.30M
Total Debt
—
Current Ratio
9.95
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$333.85
Estimated Fair Value (DCF)
$160.94
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-51.8%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $236.14M | $216.64M |
| 2 | 19.4% | $281.90M | $237.27M |
| 3 | 13.8% | $320.66M | $247.61M |
| 4 | 8.1% | $346.71M | $245.62M |
| 5 | 2.5% | $355.38M | $230.97M |
Base FCF (last actual year)
$188.91M
Terminal Value
$5.60B
Present Value of Terminal Value
$3.64B
Enterprise Value
$4.82B
Net Debt
$0
Equity Value
$4.82B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$40.72
Tangible Book Value per Share (Tangible NAV)
$40.72
Sentiment based on basic keywords (not AI) — 10 positive, 10 neutral, 0 negative out of the last 20 articles.
Benzinga · 10.9.2026
MT Newswires · 8.9.2026
MT Newswires · 8.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 3.9.2026
GlobeNewswire · 3.9.2026
Yahoo · 2.9.2026
Zacks · 2.9.2026
SeekingAlpha · 28.8.2026
Benzinga · 25.8.2026
ChartMill · 22.8.2026
MT Newswires · 17.8.2026
MT Newswires · 14.8.2026
Yahoo · 14.8.2026
24/7 Wall St. · 14.8.2026
Yahoo · 14.8.2026
MT Newswires · 14.8.2026
Krystal Biotech, Inc. (KRYS) currently has a StockIQ AI score of 56/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
KRYS currently scores 56/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, KRYS's estimated fair value is $160.94, which is 51.8% below the current price of $333.85. This is one valuation model among several signals in the fair-value category, not a price target.
KRYS's technical score is 23/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 33.9%; Earnings per share (EPS) growth: 128.0%; Free cash flow growth: 58.5%.
Based on the real signals StockIQ computed: Estimated fair value: $160.94 vs. price $333.85 (-51.8%); Price is below the 50-day average; MACD histogram is negative — falling momentum.
StockIQ has no recorded dividend payment history for KRYS.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 25 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 847 | -847 | $365.42 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 1,214 | -1,214 | $361.61 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 405 | -405 | $366.56 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 1,358 | -1,358 | $364.48 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 573 | -573 | $363.34 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 2,010 | -2,010 | $362.65 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 3,297 | -3,297 | $356.37 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 2,029 | -2,029 | $355.57 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 2,266 | -2,266 | $360.46 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 1,242 | -1,242 | $361.61 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 826 | -826 | $365.41 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 1,329 | -1,329 | $364.48 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 3,981 | -3,981 | $357.57 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 565 | -565 | $363.34 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 3,143 | -3,143 | $358.42 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 520 | -520 | $354.54 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 1,992 | -1,992 | $362.65 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 399 | -399 | $366.56 |
| Krishnan Krish S | Open Market Sale | 4.9.2026 | 3,357 | -3,357 | $359.39 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 2,320 | -2,320 | $360.47 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 520 | -520 | $354.54 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 2,006 | -2,006 | $355.57 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 3,392 | -3,392 | $359.39 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 3,962 | -3,962 | $357.57 |
| Krishnan Suma | Open Market Sale | 4.9.2026 | 3,267 | -3,267 | $356.37 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
3,347,813 shares short as of 2026-08-31 · vs. 3,202,260 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
81.7% of trading volume this week was short selling, vs. 69.0% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology